Hot-Topics Biosimilars 
Drug Channels
OCTOBER 15, 2023
View the agenda the 2023 PBM Contracting Summit to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/pbm-contracting for further details and to register. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to November 10, 2023.*
Pharma in Brief
JANUARY 10, 2024
The Court found that it was “not in the public interest” to require patients taking the infringing biosimilar to switch medications, as the infringing product was “the only 80 mg/0.8 Areas to watch in 2024 We expect the following to be hot topics in the Canadian pharma space in 2024: US mass drug imports from Canada.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
NOVEMBER 2, 2021
If congressional gridlock continues we’ll likely see CMMI test out some new payment models, including a redesign of Medicare Part D to help provide cost-sharing support for biosimilars and generics. It’s going to happen, and it will be a hot-button topic in the next election. Click to Tweet.
pharmaphorum
OCTOBER 7, 2020
Pepa has 15 years of combined experience in Regulatory Affairs (CMC) and multiple aspects of drug development and research and has participated in the approval of 15 original and biosimilar biologic license applications, focusing on microbiology product quality and sterility assurance aspects.
BioPharma Reporter
MAY 7, 2021
Kicking off these broadcasts is the hot topic of biosimilars. Today we are launching a new series called The BioPharma Pod.
Drug Discovery World
NOVEMBER 9, 2023
Dimitris Skokos, PhD, Senior Director, Cancer Immunology, Regeneron Pharmaceuticals, on: ‘Tumour-targeted costimulation via CD28 bispecific antibodies: Turning immunotherapy “cold” tumours “hot”’. The session ends with two presentations and two luncheon presentations.
Expert insights. Personalized for you.
56 
Let's personalize your content